Targeted Alpha-Therapy Market Size, Trends Report 2026


What Market Size Is Projected For The Targeted Alpha-Therapy Market By 2030?
The targeted alpha-therapy market size has grown rapidly in recent years. It will grow from $1.03 billion in 2025 to $1.2 billion in 2026 at a compound annual growth rate (CAGR) of 17.2%. The growth in the historic period can be attributed to advances in nuclear medicine research, increasing unmet needs in advanced cancers, expansion of radiopharmaceutical clinical trials, availability of medical isotopes, growth in targeted radiation therapy adoption.

The targeted alpha-therapy market size is expected to see rapid growth in the next few years. It will grow to $2.25 billion in 2030 at a compound annual growth rate (CAGR) of 17.0%. The growth in the forecast period can be attributed to increasing investment in isotope manufacturing infrastructure, rising adoption of personalized radiotherapy, expansion of targeted alpha therapies into new indications, growing regulatory support for radiopharmaceuticals, increasing collaboration between nuclear and oncology specialists. Major trends in the forecast period include increasing development of alpha-emitting radiopharmaceuticals, rising use of targeted radioligand therapies, growing focus on precision radiation delivery, expansion of isotope production capabilities, enhanced integration of targeting molecules.

Claim Your Free Report Sample Today:
https://www.thebusinessresearchcompany.com/sample.aspx?id=28337&type=smp

What Drivers Are Contributing To The Expansion Trajectory Of The Targeted Alpha-Therapy Market?
The growing focus on precision medicine is expected to propel the growth of the targeted alpha-therapy market going forward. Precision medicine refers to a healthcare approach that customizes prevention, diagnosis, and treatment based on an individual’s genetic profile, lifestyle, and environment for more effective outcomes. Precision medicine is increasing because the growing availability of genetic testing enables more accurate diagnoses and targeted treatments with improved patient outcomes. Targeted alpha-therapy helps in precision medicine by delivering highly potent alpha-emitting isotopes directly to cancer cells, enabling personalized and precise treatment while minimizing damage to healthy tissues. For instance, in March 2024, according to the American Pharmaceutical Review, a US-based journal company, global spending on precision medicine treatments was nearly $32 billion in 2022 and is projected to exceed $124 billion by 2027. Therefore, the growing focus on precision medicine is driving the growth of the targeted alpha-therapy market.

Which Primary Segments Are Included In The Detailed Analysis Of The Targeted Alpha-Therapy Market?
The targeted alpha-therapy market covered in this report is segmented –

1) By Isotope Type: Actinium-225, Radium-223, Lead-212, Bismuth-213, Other Isotype Types
2) By Application: Prostate Cancer, Bone Metastases, Pancreatic Cancer, Other Applications
3) By End-User: Hospitals, Cancer Research Institutes, Specialty Clinics, Lymphoma, Other End Users

Subsegments:
1) By Actinium-225: Ac-225 Lintuzumab, Ac-225 PSMA-617, Ac-225 DOTATATE
2) By Radium-223: Radium-223 Dichloride (Xofigo)
3) By Lead-212: Pb-212 DOTAMTATE (AlphaMedix), Pb-212 TCMC-Trastuzumab
4) By Bismuth-213: Bi-213 Lintuzumab, Bi-213 DOTATOC
5) By Other Isotope Types: Thorium-227, Astatine-211, Terbium-149

Which Trends Are Expected To Steer The Evolution Of The Targeted Alpha-Therapy Market?
Major companies operating in the targeted alpha-therapy market are focusing on developing innovative solutions such as peptide receptor radionuclide therapy to improve targeted cancer treatment efficacy, minimize off-target effects, and enhance patient outcomes. Peptide receptor radionuclide therapy (PRRT) refers to a targeted cancer treatment that delivers radioactive isotopes directly to tumor cells by binding them to peptides that specifically attach to receptors overexpressed on cancer cells, thereby minimizing damage to healthy tissue. For instance, in February 2024, RadioMedix Inc., a US-based biotechnology company, partnered with Orano Med, a US-based pharma company, and received the first targeted alpha therapy to win FDA breakthrough device designation is AlphaMedix (lead-212-Dotamtate), aimed at treating neuroendocrine tumors. It is designed to treat advanced gastroenteropancreatic neuroendocrine tumors by delivering highly potent alpha radiation directly to cancer cells while sparing healthy tissue. Its key advantage lies in the high energy and short path length of alpha particles, which cause lethal DNA damage to tumor cells with minimal toxicity. This therapy offers a promising option for patients who are naïve to or have limited response to current beta-emitter treatments, aiming to improve efficacy and safety in difficult-to-treat neuroendocrine tumors.

Which Major Corporations Play A Crucial Role In The Targeted Alpha-Therapy Market Landscape?
Major companies operating in the targeted alpha-therapy market are Bayer Aktiengesellschaft, Novartis AG, Lantheus Holdings Inc., Telix Pharmaceuticals Limited, Eckert & Ziegler Strahlen- und Medizintechnik AG, Actinium Pharmaceuticals Inc., RayzeBio Inc., ITM Isotope Technologies Munich SE, ARTBIO Inc., AdvanCell Pty Ltd., IONETIX Corporation, Abdera Therapeutics Inc., Aktis Oncology Inc., Alpha-9 Oncology Inc., Clarity Pharmaceuticals Pty Ltd., Nucleus RadioPharma, Oncoinvent AS, PanTera, Perspective Therapeutics Inc., RadioMedix Inc.

Get Your In-Depth Targeted Alpha-Therapy Market Report Now:
https://www.thebusinessresearchcompany.com/report/targeted-alpha-therapy-global-market-report

Which Geographical Region Is Projected To Lead The Targeted Alpha-Therapy Market Throughout The Forecast Period?
North America was the largest region in the targeted alpha-therapy market in 2025. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the targeted alpha-therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Contact Us:

The Business Research Company: https://thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: info@tbrc.info

Follow Us On:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

Comments

Post a Comment

Popular posts from this blog

Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Scope, Share Analysis And Growth 2025

Image
Focused on real-world business use, this report highlights what’s changing in the hypertrophic cardiomyopathy (hcm) therapeutics market and what companies should prepare for next. What Is The Projected Market Size & Growth Rate Of The Hypertrophic Cardiomyopathy (HCM) Therapeutics Market? The hypertrophic cardiomyopathy (hcm) therapeutics market size has grown marginally in recent years. It will grow from $1.34 billion in 2024 to $1.37 billion in 2025 at a compound annual growth rate (CAGR) of 1.5%. The growth in the historic period can be attributed to diagnostic advancements, increased disease awareness, drug development and approvals, rising healthcare expenditure, government initiatives and funding. The hypertrophic cardiomyopathy (hcm) therapeutics market size is expected to see steady growth in the next few years. It will grow to $1.56 billion in 2029 at a compound annual growth rate (CAGR) of 3.4%. The growth in the forecast period can be attributed to genetic research and ...
Read more

Glycomics or Glycobiology Market Scope, Share Analysis And Growth 2025

Image
Backed by rigorous analysis and deep industry knowledge, this study is designed to support growth and investment decisions in the glycomics or glycobiology market. How Big Is The Glycomics or Glycobiology Market In 2025? The glycomics or glycobiology market size has grown rapidly in recent years. It will grow from $1.85 billion in 2024 to $2.13 billion in 2025 at a compound annual growth rate (CAGR) of 14.9%. The growth in the historic period can be attributed to increased awareness of glycans in biological systems, expansion of glycan-related database and resources, rise in collaborative research initiatives, advancements in glycan synthesis and engineering, glycan biomarker identification. The glycomics or glycobiology market size is expected to see rapid growth in the next few years. It will grow to $3.99 billion in 2029 at a compound annual growth rate (CAGR) of 17.0%. The growth in the forecast period can be attributed to glycan-focused artificial intelligence (AI) and data analy...
Read more

Smart Crop Monitoring Market Overview, Analysis And Demand By 2034

Image
Aimed at strategic decision-makers, this report explores current opportunities, emerging trends, and market dynamics shaping the smart crop monitoring sector. How Big Is The Smart Crop Monitoring Market In 2025? The smart crop monitoring market size has grown rapidly in recent years. It will grow from $3.47 billion in 2024 to $4.09 billion in 2025 at a compound annual growth rate (CAGR) of 18.0%. The growth in the historic period can be attributed to rising demand for high crop production, increasing global population, significant growth in IOT technology, rising need for sustainable agricultural practices, and increasing regulatory pressures. The smart crop monitoring market size is expected to see rapid growth in the next few years. It will grow to $7.83 billion in 2029 at a compound annual growth rate (CAGR) of 17.6%. The growth in the forecast period can be attributed to the development of automated irrigation systems, the growing trend of farm-to-table movements, an increase in ag...
Read more